Target intelligence / Profile preview

NADPH-cytochrome P450 reductase (POR)

Target
POR
Molecular classification
Enzyme, Oxidoreductase, Flavoprotein
01

Overview

NADPH-cytochrome P450 reductase (POR) is an essential membrane-bound flavoprotein located in the endoplasmic reticulum. It serves as the obligatory and sole electron donor for all microsomal (type II) cytochrome P450 (CYP) enzymes, which are responsible for the metabolism of approximately 75% of clinical drugs, as well as endogenous steroids, cholesterol, and fatty acids. POR transfers electrons from NADPH through its FAD and FMN domains to the heme iron of its CYP partners.

In addition to its physiological role in drug clearance and steroidogenesis, POR is a critical target in oncology. It mediates the bioreductive activation of hypoxia-activated prodrugs (HAPs) such as tirapazamine, mitomycin C, and evofosfamide, converting them into cytotoxic species selectively within the hypoxic microenvironment of solid tumors. Genetic mutations in the POR gene lead to cytochrome P450 oxidoreductase deficiency (PORD), which causes disordered steroidogenesis, ambiguous genitalia, and skeletal malformations characteristic of Antley-Bixler syndrome. Consequently, modulating POR activity represents a dual-edged sword, offering therapeutic opportunities in cancer while posing significant risks of endocrine and developmental toxicities.

Other names
Cytochrome P450 oxidoreductaseNADPH-dependent cytochrome P450 reductaseP450 oxidoreductaseCPRCYPORP450RNADPH-hemoprotein reductase
02

Mechanism of action

Bioreductive activation of prodrugs, one-electron reduction, and redox cycling

03

Biological functions

Electron transferDrug metabolismSteroidogenesisXenobiotic metabolismCholesterol biosynthesisHeme catabolismFatty acid metabolism
04

Disease associations

CancerCongenital adrenal hyperplasiaAntley-Bixler syndromeDisordered steroidogenesisDisorders of sex development
05

Safety considerations

Adrenal insufficiencyDisordered steroidogenesisSkeletal malformations (Antley-Bixler syndrome phenotype)Altered drug clearance and drug-drug interactionsSystemic toxicity from off-target activation
06

Interacting drugs

11 more in the full profile.

07

Biomarkers

POR expression levelPOR gene mutationsPOR polymorphismsHypoxia levels

Beyond the preview

Go deeper on NADPH-cytochrome P450 reductase (POR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADPH-cytochrome P450 reductase (POR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call